Marker Therapeutics is trading 5.18% up now at $1.31, primarily as stronger biotechnology sentiment lifts the XBI sector benchmark, up 2.75%.
- No fresh company-specific announcement was identified for September 3, 2026; recent analyst commentary is stale rather than a new catalyst.
- Patent-related gains elsewhere in biotech and continued positive momentum are supporting sector strength.
- Broader risk appetite is also supportive: the Nasdaq Composite is up 0.69% and the S&P 500 is up 0.42%.